$MDGEF $MDG1 new focus on off-the-shelf TCR-TCE
https://medigene.com/wp-content/uploads/MDG-Corporate-Deck-26-November-2024.pdf
restructing to reduce costs and support commercal partners WuXi, BioNTech, and Regeneron
https://medigene.com/wp-content/uploads/Transcript.pdf
$MDGEF R&D webcast starting now via Edison https://www.edisongroup.com/event/making-the-ordinary-extraordinary-next-generation-t-cell-receptors-for-precision-immunotherapies/33995/
@AI_Infested it is the TCR from Adaptimmune step mother Medigene $MDGEF (also TCR partner to BioNTech & RoiVant ) sold to bluebird / 2seventy / regeneron and further dealed for China with JW therapeutics
(after Afami-cel progress)
https://www.globenewswire.com/news-release/2023/01/18/2591155/0/en/Medigene-Receives-3-Million-Milestone-Payment-from-2seventy-bio.html
$ADAPY potential competition regarding TCR-T targeting NY-ESO-1 from the step-mother $MDGEF (maybe in coordination with $BNTX ?) https://twitter.com/biotechradar_eu/status/1592559545175273472?s=20&t=HqGGqJJIO1IEP5_Wm8fCtA
$BNTX can someone please buy a share of medigene on the nasdaq so we can have a working $MDGEF chart again? it is since 04.03. not been bought and the ticker has fallen asleep. Medigene is Biontech's partner in the TCR program in cancer immunotherapy. They had earnings today and have a 10% increase. Worth it!
https://investors.biontech.de/news-releases/news-release-details/biontech-and-medigene-announce-global-collaboration-advance-t/
